6 recruiting, 1 completed. 4 Phase 3, 2 Phase 1, 1 Phase 2.
By phase and status
Follow Efimosfermin alfa: new trials by email Literature Review of Efimosfermin alfa trials Research Report on Efimosfermin alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD) Efimosfermin alfa, Placebo - Liver Diseases, Alcoholic Phase 2 Recruiting 274 2026-08-31 2026-09-30 A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) Efimosfermin alfa, Placebo - Metabolic Dysfunction-associated Steatohepatitis Phase 3 Recruiting 380 2026-07-22 2026-09-30 A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) Efimosfermin alfa, Placebo - Metabolic Dysfunction-associated Steatohepatitis Phase 3 Recruiting 1740 2026-07-22 2026-09-30 A Study of Efimosfermin Alfa in Adults With Hepatic Impairment Efimosfermin alfa - Non-alcoholic Fatty Liver Disease Phase 1 Recruiting 32 2026-03-13 2026-06-09 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry Efimosfermin alfa, Placebo - Non-alcoholic Fatty Liver Disease Phase 1 Completed 30 2026-03-05 2026-09-21 A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH Efimosfermin Alfa, Placebo - Non-alcoholic Fatty Liver Disease Phase 3 Recruiting 1250 2025-12-12 2026-09-17 A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH Efimosfermin alfa, Placebo - Non-alcoholic Fatty Liver Disease Phase 3 Recruiting 1200 2025-10-24 2026-07-27
Conditions studied Non-alcoholic Fatty Liver Disease (4) · Fatty Liver (2) · Fibrosis (2) · Liver Diseases, Alcoholic (1)
Sponsors GlaxoSmithKline (7)
Countries United States (6) · Japan (4) · New Zealand (3) · Australia (2) · Hong Kong (2) · Saudi Arabia (2) · Argentina (1) · Canada (1) · France (1) · Germany (1) · Puerto Rico (1) · Taiwan (1)
NIH funding 2025 (2)